Create a narrative

GSK Community

Our community narratives are driven by numbers and valuation.

Value any stock for free in seconds

Get alerts and valuation updates

Participate in discussions

GSK logo
GSK
WA
WarrenAI
Based on Analyst Price Targets

Innovative Specialty Medicines And Vaccine Success Steer Future Growth Amid Challenges

Key Takeaways Strong growth in Specialty Medicines and new product launches expected to drive revenue, particularly in HIV, Respiratory, and Oncology. Expanding portfolio with new vaccines and HIV advancements anticipated to impact earnings and market share positively.
View narrative
UK£19.07
FV
29.0% undervalued intrinsic discount
4.36%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
7 days ago author updated this narrative